Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Unknown 15Recruiting 13Not yet recruiting 5Completed 5Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 23Head & Neck 6Thoracic 5Breast 5Other solid neoplasm 3Gynecologic 3Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Gastrointestinal Neoplasms 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × camrelizumab × Breast × Clear all
NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
441 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04805736 2024-01-05

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Completed
60 enrolled
Breast

Breast Neoplasms

NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
99 enrolled
BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
32 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03394287 2020-10-23

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Completed
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡